Brand Name :
Elidel
Synonyms :
pimecrolimus topical
Class :
Calcinuerin Inhibitors, Topical Immunosuppressants
Brand Name :
Elidel
Synonyms :
pimecrolimus topical
Class :
Calcinuerin Inhibitors, Topical Immunosuppressants
Dosage Forms & Strengths
Cream
1%
Apply a tiny coating to the affected region every 12 hours, limiting the application to that area and continuing as long as the symptoms remain
Dosage Forms & Strengths
Cream
1%
<2 years: Safety and efficacy not established
>2 years: Apply a tiny coating to the afflicted region every 12 hours, limiting the application to that area, and continuing as long as the symptoms remain
Refer adult dosing
may increase the tacrolimus immunosuppressive effect
may increase the tacrolimus immunosuppressive effect
may increase the tacrolimus immunosuppressive effect
may increase the tacrolimus immunosuppressive effect
may increase the tacrolimus immunosuppressive effect
may increase the nephrotoxic effect of tacrolimus
may increase the immunosuppressive effect of tacrolimus
may increase the immunosuppressive effect of tacrolimus
may increase the immunosuppressive effect of tacrolimus
may increase the immunosuppressive effect of tacrolimus
may increase the immunosuppressive effect of tacrolimus
may increase the immunosuppressive effect of tacrolimus
may reduce the therapeutic effect of vaccines
poliovirus vaccine, live, trivalent
may reduce the therapeutic effect of vaccines
poliovirus vaccine inactivated
may reduce the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)
may reduce the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may increase the immunosuppressive effect of tacrolimus
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with rabies vaccine
may decrease the therapeutic effect when combined with sipuleucel-t
may decrease the therapeutic effect when combined with vaccines
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with leflunomide
may decrease the diagnostic effect when combined with coccidioides immitis test
may decrease the therapeutic effect when combined with COVID-19 vaccine
may increase the immunosuppressive effect of immunosuppressive agents
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased adverse effect when combined with dengue tetravalent vaccine
may have an increased immunosuppressive effect when combined with immunosuppressants
may increase the immunosuppressive effect of tacrolimus
may have an increased adverse effect when combined with nadofaragene firadenovec
may have an increased immunosuppressive effect when combined with natalizumab
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with ruxolitinib
may have an increasingly adverse effect when combined with talimogene laherparepvec
may have an increased immunosuppressive effect when combined with tofacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
poliovirus vaccine, live, trivalent
may enhance the adverse/toxic effect
poliovirus vaccine inactivated
may enhance the adverse/toxic effect
measles, mumps, rubella, and varicella vaccine, live (Rx)
may enhance the adverse/toxic effect
measles mumps and rubella vaccine, live
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
smallpox (vaccinia) vaccine, live
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may have an increasingly adverse effect when combined with immunosuppressants
methotrexate can also enhance the immunosuppressive effect of tacrolimus (Topical)
may increase the serum concentration of pimecrolimus
may increase the serum concentration of pimecrolimus
may increase the serum concentration of pimecrolimus
may increase the serum concentration of pimecrolimus
may increase the serum concentration of pimecrolimus
respiratory syncytial virus vaccine, adjuvanted
may reduce the therapeutic effect of vaccines
respiratory syncytial virus (RSV) vaccine
may reduce the therapeutic effect of vaccines
may have an increased adverse effect when combined with BCG products
may have an increased immunosuppressive effect when combined with cladribine
may increase the therapeutic effect of immunosuppressants
may decrease the therapeutic effect when combined with brincidofovir
may have an increased immunosuppressive effect when combined with inebilizumab
may have an increased immunosuppressive effect when combined with ocrelizumab
may have an increased immunosuppressive effect when combined with ofatumumab
may decrease the therapeutic effect when combined with pidotimod
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with tacrolimus
Actions and Spectrum:
Frequency defined
>10%
Headache (7-25%)
Nasopharyngitis (8-27%)
Bronchitis (<11%)
Burning sensation (2-26%)
Fever (1-13%)
Cough (2-16%)
Upper respiratory tract infection (4-19%)
<1%
Malignant melanoma
Basal cell carcinoma of the skin
Flushing
Eczema
Squamous cell carcinoma
Septic arthritis
Ocular irritation
Skin discoloration
Malignant lymphoma
Frequency not defined
Paraesthesia
Dryness
Skin infection
Desquamation
Application site pain
Rash
Black box warning:
Contraindications/caution:
Contraindications:
Caution:
Pregnancy consideration: C
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Pharmacodynamics:
pimecrolimus inhibits the activity of calcineurin, a protein that plays a vital role in the activation of T-cells in the immune system. T-cells are involved in the immune response and contribute to inflammation and itching, common symptoms of atopic dermatitis. By suppressing the activity of calcineurin, pimecrolimus reduces the activation of T-cells and therefore reduces inflammation and itching in the affected area
Pharmacokinetics:
Absorption
pimecrolimus is a lipophilic compound well absorbed through the skin. It penetrates the skin and reaches the deeper layers, where it exerts its effects. After topical application, pimecrolimus is absorbed into the systemic circulation, although systemic absorption is minimal.
Distribution
pimecrolimus is highly bound to plasma proteins (approximately 99%). The drug is distributed throughout the body and accumulates in the liver but not in the skin.
Metabolism
pimecrolimus is extensively metabolized in the liver by the cytochrome P450 enzyme system, primarily by CYP3A4. The metabolites are inactive and are excreted in the urine.
Elimination and Excretion
pimecrolimus and its metabolites are excreted primarily in the urine, with a small amount excreted in the feces. The elimination half-life of pimecrolimus is approximately 30 hours, which is relatively short
Administration:
Patient information leaflet
Generic Name: pimecrolimus topical
Pronounced: [ PIM-e-KROE-li-mus-TOP-ik-al ]
Why do we use pimecrolimus topical?
pimecrolimus is used to treat atopic dermatitis, also known as eczema because it is an effective topical immunomodulator that can help reduce inflammation and itching associated with this condition. Atopic dermatitis is a chronic inflammatory skin disorder characterized by itchy, red, and scaly patches on the skin.